首頁 > 市場調查報告書 > 製藥

生物製劑

人類微生物組市場規模、佔有率和成長分析（按產品、疾病、類型、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1901915

人類微生物組市場規模、佔有率和成長分析（按產品、疾病、類型、最終用戶和地區分類）—2026-2033年產業預測

Human Microbiome Market Size, Share, and Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 201 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，人類微生物組市場規模將達到 13.3 億美元，到 2025 年將達到 17.5 億美元，到 2033 年將達到 159.8 億美元，在預測期（2026-2033 年）內複合年成長率為 31.8%。

由於人類微生物組與呼吸系統和免疫系統健康密切相關，該市場正經歷顯著成長。腸道微生物組尤其因其在增強免疫功能方面的作用而備受認可。某些微生物群落的紊亂被認為與呼吸系統疾病有關，這推動了基於微生物組的治療方法的發展，旨在改善包括病毒感染在內的呼吸系統疾病相關健康狀況。文明病的日益增加和人口老化進一步推動了市場的擴張。次世代定序和先進的微生物表徵技術等進步也在改變該領域的模式。總而言之，不斷增加的研究投入以及人們對微生物組及其對健康影響的認知不斷提高，是塑造這個蓬勃發展市場未來的關鍵因素。

人類微生物組市場促進因素

慢性疾病（例如胃腸道疾病、肥胖症和糖尿病）發病率的不斷上升是推動人類微生物組市場發展的主要因素。越來越多的研究表明腸道菌群與這些健康狀況密切相關，從而推動了以微生物組為中心的治療方案和相關研究的需求。醫療保健提供者和患者對微生物組相關問題的認知和興趣日益增強，促使對微生物組相關產品的研究、創新和商業化投入顯著增加。這一趨勢凸顯了理解微生物組在健康中的作用的重要性，有助於推動治療方案的進步並改善市場模式。

人類微生物組市場限制因素

人類微生物組領域的一大障礙是研發相關的巨額資金負擔。研究微生物並將其轉化為有效治療方法的複雜性需要大量投資。此外，進行臨床試驗和獲得監管核准批准的成本可能非常高昂，阻礙產品創新步伐，並限制整體市場成長。這種資金負擔給那些致力於推進產品開發並利用微生物組潛力的公司帶來了挑戰，最終影響了它們及時向消費者提供新解決方案的能力。

人類微生物組市場趨勢

人類微生物組市場正經歷著向個人化醫療的顯著轉變，這反映出人們越來越重視根據每位患者獨特的微生物譜量身訂做治療性介入。基因測序和數據分析技術的進步推動了這一轉變，使研究人員和製藥公司能夠開發標靶治療和診斷方法。因此，醫療服務提供者能夠為微生物組相關疾病提供更有效的解決方案，從而改善患者的治療效果和滿意度。這種個人化方法不僅促進了創新治療方法的開發，也為更深入地了解微生物組在整體健康中的作用鋪平了道路，從而激發了人們對這一新興領域的進一步投資和關注。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Seres Therapeutics, Inc.（US）
Ferring Pharmaceuticals（Switzerland）
Biomebank（Australia）
Nestle SA（Switzerland）
Sanofi（France）
Seed Health, Inc.（US）
Enterome（France）
Pendulum（US）
Quantbiome, Inc.（Dba Ombre）（US）
Vedanta Biosciences, Inc.（US）
Maat Pharma SA（France）
International Flavors & Fragrances, Inc.（US）
Optibiotx Health Plc（UK）
Synlogic, Inc.（US）
Guangzhou Zhiyi Biotechnology Co., Ltd.（China）
Aobiome（US）
Siolta Therapeutics（US）
Alveolus Bio, Inc.（US）
MRM Health NV（Belgium）
Biome Inc（US）
Sanzyme Biologics（India）
Biomx（Israel）
Nubiyota（US）
Quorum Innovations（US）

簡介目錄

Product Code: SQMIG35H2299

Human Microbiome Market size was valued at USD 1.33 Billion in 2024 and is poised to grow from USD 1.75 Billion in 2025 to USD 15.98 Billion by 2033, growing at a CAGR of 31.8% during the forecast period (2026-2033).

The human microbiome market is witnessing significant growth driven by its crucial connections to respiratory and immune health. The gut microbiome, in particular, is recognized for its role in enhancing immune function. Disruptions in specific microbial populations have been implicated in respiratory issues, prompting the development of microbiome-based therapies aimed at improving health outcomes related to respiratory conditions, including viruses. The rising prevalence of lifestyle-related diseases, alongside an aging population, further propels market expansion. Advances in technology, such as next-generation sequencing and enhanced microbial characterization techniques, are also transforming the landscape. Overall, increased research efforts and heightened awareness of the microbiome's impact on health are key factors shaping the future of this thriving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Microbiome Market Segments Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal issues, obesity, and diabetes, significantly fuels the human microbiome market. Research increasingly illustrates the connection between gut microbiota and these health conditions, leading to heightened demand for treatment options and investigative studies centered on the microbiome. As awareness and interest grow among both healthcare providers and patients, there is a notable surge in investment toward research, innovation, and the commercialization of microbiome-related products. This trend emphasizes the importance of understanding the microbiome's role in health, driving advances in therapeutic solutions and enhancing the overall market landscape.

Restraints in the Human Microbiome Market

A significant obstacle in the human microbiome sector is the substantial financial burden associated with research and development efforts. The complexities involved in studying microbes and transforming these insights into effective treatments necessitate considerable investment. Additionally, the expenses associated with conducting clinical trials and navigating regulatory approvals can escalate, hindering the pace of product innovation and limiting overall market growth. This financial strain poses a challenge for companies striving to advance their offerings and capitalize on the potential of the microbiome, ultimately impacting their ability to bring new solutions to consumers in a timely manner.

Market Trends of the Human Microbiome Market

The human microbiome market is witnessing a notable trend towards personalized medicine, reflecting a growing emphasis on tailoring therapeutic interventions to individual patients based on their unique microbial profiles. This shift is propelled by advancements in genomic sequencing and data analytics, enabling researchers and pharmaceutical companies to develop targeted treatments and diagnostics. As a result, healthcare providers can offer more effective solutions for microbiota-related diseases, enhancing patient outcomes and satisfaction. This personalized approach not only fosters the development of innovative therapies but also paves the way for a deeper understanding of the microbiome's role in overall health, driving further investment and interest in this evolving field.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Technology Analysis
Patent Analysis
Regulatory Landscape

Human Microbiome Market by Product

Market Overview
Drugs
Probiotics
Prebiotics
Synbiotics

Human Microbiome Market by Disease

Market Overview
Infectious Diseases
Gastrointestinal Diseases
Endocrine & Metabolic Disorders
Other Diseases

Human Microbiome Market by Type

Market Overview
Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
Live Biotherapeutic Product
Others

Human Microbiome Market by End User

Market Overview
Hospitals and Clinics
Long-Term Care Facilities
Other End Users

Human Microbiome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Seres Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomebank (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seed Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enterome (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pendulum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quantbiome, Inc. (Dba Ombre) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vedanta Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Maat Pharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
International Flavors & Fragrances, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optibiotx Health Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aobiome (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siolta Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alveolus Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MRM Health NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biome Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanzyme Biologics (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomx (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nubiyota (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quorum Innovations (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments